| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | IC50 | 6.8 [1] |
| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | Ki | 8.0 [1] |
| Ilomastat | IC50 | 0.55 [1] |
| Ilomastat | Ki | 0.57 [1], 0.69 [2] |
| Marimastat | IC50 | 0.79 [1], 1.5 [2], 1.6 [3], 10000.0 [4] |
| Marimastat | Ki | 1.0 [1], 11.0 [2] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | IC50 | 0.11 [1], 2.0 [2], 3.0 [3] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | Ki | 0.55 [1], 0.58 [2] |
| Prinomastat | IC50 | 0.05 [1], 0.2 [2], 0.26 [3], 0.4 [4] |
| N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)acetamide | IC50 | 200.0 [1] |
| n-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide | IC50 | 5.0 [1], 5.01 [2] |
| Batimastat | IC50 | 0.2 [1], 0.6 [2], 0.67 [3], 25.0 [4] |
| 2-((4-Phenoxyphenylsulfonyl)methyl)thiirane | Ki | 400.0 [1], 600.0 [2] |
| Mmp inhibitor II | IC50 | 1.8 [1], 2.7 [2] |
| Mmp inhibitor II | Ki | 30.0 [1] |
| (2S)-2-[[4-(4-Methoxyphenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 747.0 [1], 2187.76 [2], 2200.0 [3] |
| N-(3-Methoxybenzyl)-4-Oxo-3,4-Dihydroquinazoline-2-Carboxamide | IC50 | 10000.0 [1] |
| N-(4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl)acetamide | IC50 | 529.1 [1] |
| N-(4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl)acetamide | Ki | 130.0 [1] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | IC50 | 12.0 [1] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | Ki | 2.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | IC50 | 4.8 [1], 5.9 [2], 34.0 [3] |
| Cipemastat | IC50 | 2.4 [1], 58.0 [2] |
| Cipemastat | Ki | 59.0 [1] |
| N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide | IC50 | 130.0 [1] |
| N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide | Ki | 143.0 [1], 144.54 [2] |
| (2R)-2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamide | Ki | 27.0 [1] |
| (R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamide | IC50 | 6.7 [1] |
| CID 6914621 | IC50 | 10340.0 [1] |
| CID 6914621 | Ki | 10340.0 [1] |
| CID 10370504 | IC50 | 840.0 [1] |
| 4-[(4-But-2-ynoxyphenyl)sulfonylmethyl]-N-hydroxy-1-propan-2-ylsulfonylpiperidine-4-carboxamide | IC50 | 1670.0 [1] |
| N-Hydroxy-4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxamide | IC50 | 1.5 [1] |
| (2S,3R)-2-(Cyclopropylmethylamino)-N-hydroxy-N'-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(3-hydroxyphenyl)methyl]butanediamide | Ki | 4468.0 [1] |
| N-Hydroxy-2-[(4-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-acetamide | Ki | 0.6 [1] |
| (2S)-2-[[4-(4-Fluorophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 64000.0 [1], 64565.42 [2] |
| Benzyl 6-Benzyl-5,7-Dioxo-6,7-Dihydro-5h-[1,3]thiazolo[3,2-C]pyrimidine-2-Carboxylate | IC50 | 30000.0 [1], 100000.0 [2] |
| (2R,3R,4R,5S)-N,3,4,5-Tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide | Ki | 0.06 [1] |
| N-Hydroxy-2-[[4-(4-methoxyphenyl)phenyl]methyl]-1,1-dioxo-1,2-thiazolidine-3-carboxamide | Ki | 46.7 [1] |
| (8S,11R,12S)-12-N-Hydroxy-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-11-[[4-[2-(trifluoromethyl)phenyl]phenyl]methyl]-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide | Ki | 2000.0 [1] |
| N-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-(4-nitro-benzyl)-amino]-acetamide | Ki | 30.9 [1], 31.0 [2] |
| N-Hydroxy-2-[(4-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-acetamide | Ki | 2.0 [1] |
| ((4'-Chloro-[1,1'-biphenyl]-4-yl)sulfonyl)valine | IC50 | 15848.93 [1], 16000.0 [2] |
| (3R)-2-[Ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide | Ki | 5.05 [1] |
| (6S,7S)-N-Hydroxy-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 650.0 [1] |
| 2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methoxybenzenecarbohydroximic acid | IC50 | 22.91 [1], 23.0 [2] |
| 2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methylbenzenecarbohydroximic acid | IC50 | 22.91 [1], 23.0 [2] |
| 2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methylbenzenecarbohydroximic acid | Ki | 23.0 [1] |
| (2R)-2-[Benzyl-[4-(2-fluoroethoxy)phenyl]sulfonylamino]-N-hydroxy-3-methylbutanamide | IC50 | 50.0 [1] |
| 1-[4-(4-Chlorophenoxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone | Ki | 0.7 [1], 0.72 [2] |
| 2-[4-(2-Butynyloxy)phenylsulfonylamino]acetohydroximic acid | IC50 | 753.0 [1], 758.58 [2], 890.0 [3] |
| N-Hydroxy-N-[1-(2-hydroxyethoxy)-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpropan-2-yl]formamide | IC50 | 0.3 [1] |
| N-[1-(1,4-Dioxaspiro[4.5]decan-8-yl)-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide | IC50 | 2.0 [1] |
| N-[(3S)-3,4-Dihydroxy-1-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylbutan-2-yl]-N-hydroxyformamide | IC50 | 0.09 [1] |
| Caffeic acid | IC50 | 10.0 [1], 21.22 [2] |
| N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride | IC50 | 10.0 [1], 40.0 [2] |
| Tanomastat | IC50 | 301.0 [1] |
| Tanomastat | Ki | 301.0 [1] |
| (S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid | IC50 | 7900.0 [1], 7943.28 [2] |
| Apratastat | IC50 | 82.0 [1] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | Ki | 1.0 [1], 10.0 [2] |
| Unii-Q56UE7E40Y | IC50 | 304.0 [1], 428.0 [2] |
| (R)-5-(6-Cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide | IC50 | 10000.0 [1] |
| N-[(1S)-1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide | IC50 | 0.5 [1], 1.4 [2] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamide | Ki | 26.92 [1], 27.0 [2] |
| Mmp-2/mmp-9 inhibitor i | IC50 | 240.0 [1], 2700.0 [2] |
| cis-2-Aminocyclohexylcarbamoylphosphonic acid | IC50 | 20000.0 [1] |
| (3R)-3-[[(2S)-1-[[(1S)-2-Methoxy-1-phenylethyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-6-(3-methyl-4-phenylphenyl)hexanoic acid | IC50 | 30400.0 [1] |
| N-[(2S)-1-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-N-hydroxyformamide | IC50 | 120.0 [1] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxyacetamide | Ki | 41.69 [1], 42.0 [2] |
| D-Tryptophan, N-[[5-[2-(4-methylphenyl)ethynyl]-2-thienyl]sulfonyl]- | IC50 | 9.6 [1], 23.0 [2] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | IC50 | 0.38 [1] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | Ki | 1.4 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 0.18 [1], 0.2 [2] |
| 4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic Acid | IC50 | 30000.0 [1], 100000.0 [2] |
| (2R)-N'-Hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2-[(3-hydroxyphenyl)methyl]butanediamide | Ki | 3324.0 [1] |
| (3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]benzoyl]amino]oxane-3-carboxamide | Ki | 2128.0 [1], 10000.0 [2] |
| 2-(Biphenyl-4-ylsulfonamido)-N-hydroxyacetamide | IC50 | 34.0 [1] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | Ki | 1.8 [1] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxypropanamide | Ki | 34.67 [1], 35.0 [2] |
| 4-[4-(Thiirane-2-ylmethylsulfonyl)phenoxy]phenol | Ki | 160.0 [1] |
| (2S)-3-Methyl-2-[(4-phenylphenyl)sulfonylamino]butanoic acid | IC50 | 25703.96 [1], 26000.0 [2] |
| Hydroxamate analogue 22 | IC50 | 0.54 [1], 3.0 [2] |
| 1-Cyclopropyl-N-hydroxy-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 0.15 [1], 1.0 [2] |
| 2-[Methyl[4-(2-butynyloxy)phenylsulfonyl]amino]-3-methyl-5-bromobenzohydroximic acid | IC50 | 304.0 [1] |
| L-Valine,N-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]- | IC50 | 38000.0 [1], 38018.94 [2] |
| Tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylate | Ki | 1.0 [1] |
| N-Hydroxy-2-(4-methoxyphenylsulfonyl)-2-(prop-2-ynyl)pent-4-ynamide | IC50 | 141.0 [1] |
| (R,E)-N-Hydroxy-2-(4-methoxyphenylsulfonyl)-2-methyl-5-phenylpent-4-enamide | IC50 | 16.0 [1] |
| (3S)-N-Hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamide | IC50 | 3.6 [1] |
| 2-Allyl-N-hydroxy-2-(4-methoxyphenylsulfonyl)pent-4-enamide | IC50 | 35.0 [1] |
| 2-Pyrimidinecarboxamide, hexahydro-N-hydroxy-1,3-bis((4-methoxyphenyl)sulfonyl)- | IC50 | 3.9 [1] |
| 2-[Benzyl(4-methoxyphenylsulfonyl)amino]benzenecarbohydroximic acid | IC50 | 645.65 [1], 650.0 [2] |
| 4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl methanesulfonate | Ki | 5.0 [1] |
| (6S,7S)-N-Hydroxy-6-(4-phenyl-3,6-dihydro-2H-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 113.0 [1] |
| 5-Methyl-5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trione | IC50 | 52.0 [1] |
| 5-Methyl-5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trione | Ki | 52.0 [1] |
| 2-[Methyl(4-methoxyphenylsulfonyl)amino]-3-methyl-5-bromobenzohydroximic acid | IC50 | 11.0 [1] |
| N-Hydroxy-2-[(2-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-propionamide | Ki | 4.37 [1], 4.4 [2] |
| N-Hydroxy-2-[(2-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-propionamide | Ki | 1.0 [1] |